RxDoctor Payments Data

Ateet Kosaraju, MD

Interventional Cardiology · Hickory, NCNPI 1225482581

Payments from drug & device makers

$6,392in general payments, 2019–2025

Across 91 payments — averaging $70.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Boston Scientific$2K
  • Medtronic$711
  • Biotronik Inc.$563
  • Shockwave Medical, Inc$415
  • Abiomed$267
  • plus $970 from 16 others

What the payments were for

  • Grants$5368%
  • Travel & lodging$1,12418%
  • Food & beverage$4,36068%
  • Education$3726%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,392 in reported general payments places this provider in the 40th percentile of 180 interventional cardiology providers in North Carolina.

See all interventional cardiology providers in North Carolina

Medicare billing

Part B allowed, 2024
$47,636
Medicare patients
255
Services billed
656

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban40$35,440
EntrestoSacubitril/Valsartan27$34,253
Repatha SureclickEvolocumab21$13,693
FarxigaDapagliflozin Propanediol11$6,335
Ranolazine ErRanolazine30$2,170
Atorvastatin Calcium72$964
Ezetimibe44$510
Carvedilol54$485
ClopidogrelClopidogrel Bisulfate43$437
Metoprolol Succinate37$358
Amlodipine Besylate28$298
Furosemide62$274
Isosorbide Mononitrate ErIsosorbide Mononitrate23$229
Nitroglycerin14$212
Metoprolol Tartrate28$187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$20$35,44040 claims
NovartisEntresto$77$34,25327 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 180 interventional cardiology providers in North Carolina.

Other interventional cardiology in Hickory

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →